source
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
- Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcyWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 6d ago↗ source
- Karyopharm files for Chapter 11 and plans auction with Gamida Cell parent Ayrmid as lead bidder